Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17784028 | 0.91 | SLC6A4 (0.38) | SLC6A4SLC6A3ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL17784027 | 0.88 | ALDH1A1 (0.41) | SLC6A4SLC6A3ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL21760848 | 0.84 | ALDH1A1 (0.40) | SLC6A4SLC6A3ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL17784138 | 0.75 | LMNA (0.39) | ALDH1A1HTTDPP4DPP8DPP9 | |
| SCHEMBL17784031 | 0.68 | POLB (0.35) | — | |
| SCHEMBL12688430 | 0.68 | CHRNB2 (0.34) | SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL15192136 | 0.66 | SLC6A3 (0.48) | SLC6A4SLC6A3ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL20817354 | 0.66 | KDM1A (0.45) | SLC6A4SLC6A3 | |
| SCHEMBL4714304 | 0.66 | KDM1A (0.53) | SLC6A4SLC6A3ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4717194 | 0.66 | KDM1A (0.53) | SLC6A4SLC6A3ALDH1A1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710959-B2 | Sulfide alkyl compounds for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| EP-3227262-B1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS INC (US) | 2020-05-13 | — | — | EP | disclosed |
| US-20190202780-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-10196351-B2 | Sulfide alkyl compounds for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170298014-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC | 2017-10-19 | — | — | US | disclosed |
| EP-3227262-A1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | Novira Therapeutics Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| US-9597332-B2 | Sulfide alkyl compounds for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| WO-2016089990-A1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| US-20160151375-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202780-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | HAVCR2, HCCS, CBS | SLC6A4 2576/4885SLC6A3 2739/4885ALDH1A1 1765/4885 |
| US-20160151375-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | HAVCR2, HCCS, CBS | SLC6A4 2576/4885SLC6A3 2739/4885ALDH1A1 1765/4885 |
| US-10196351-B2 | Sulfide alkyl compounds for HBV treatment | HAVCR2, HCCS, CBS | SLC6A4 2576/4885SLC6A3 2739/4885ALDH1A1 1765/4885 |
| US-20170298014-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | HAVCR2, HCCS, CBS | SLC6A4 2576/4885SLC6A3 2739/4885ALDH1A1 1765/4885 |
| US-10710959-B2 | Sulfide alkyl compounds for HBV treatment | HAVCR2, HCCS, CBS | SLC6A4 2576/4885SLC6A3 2739/4885ALDH1A1 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.